1 results
25/Feb/2019
25/Feb/2019
DOI: 10.31744/einstein_journal/2019GS4414
ABSTRACT Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects. Results Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0.492 and 0.999, respectively, in Quality-Adjusted […]
Keywords: Cost-benefit analysis; Drug costs; Drug therapy/economy; Hormone therapy/economy; Placebo; Prostatic neoplasms/drug therapy; Public health